مورد إلكتروني
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
| العنوان: | Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. |
|---|---|
| المؤلفون: | Coutré, Steven E |
| المصدر: | Clinical cancer research : an official journal of the American Association for Cancer Research; vol 23, iss 5, 1149-1155; 1078-0432 |
| بيانات النشر: | eScholarship, University of California 2017-03-01 |
| تفاصيل مُضافة: | Coutré, Steven E Furman, Richard R Flinn, Ian W Burger, Jan A Blum, Kristie Sharman, Jeff Jones, Jeffrey Wierda, William Zhao, Weiqiang Heerema, Nyla A Johnson, Amy J Tran, Anh Zhou, Cathy Bilotti, Elizabeth James, Danelle F Byrd, John C O'Brien, Susan |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Purpose: Ibrutinib, a first-in-class, once-daily, oral inhibitor of Bruton tyrosine kinase, promotes apoptosis, and inhibits B-cell proliferation, adhesion, and migration. Ibrutinib has demonstrated single-agent efficacy and acceptable tolerability at doses of 420 and 840 mg in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who were treatment-naïve (TN) or had relapsed/refractory (R/R) CLL after ≥1 prior therapy in a phase Ib/II study (PCYC-1102). Subsequently, the ibrutinib 420 mg dose was approved in CLL.Experimental Design: We report data with 44 months of follow-up on 94 patients with TN and R/R CLL/SLL receiving ibrutinib 420 mg once-daily in PCYC-1102 and the long-term extension study PCYC-1103.Results: Ninety-four CLL/SLL patients (27 TN, 67 R/R) were treated with ibrutinib (420 mg/day). Patients with R/R disease had received a median of four prior therapies (range, 1-12). Responses were rapid and durable and median duration of response was not reached. Best overall response was 91% [85% TN (complete response, CR 26%) and 94% R/R (9% CR)]. Median progression-free survival (PFS) was not reached in either group. The 30-month PFS rate was 96% and 76% for TN and R/R patients, respectively. Ibrutinib was well tolerated with extended follow-up; rates of grade ≥3 cytopenias and fatigue, as well as discontinuations due to toxicities decreased over time.Conclusions: Single-agent ibrutinib at 420 mg once-daily resulted in durable responses and was well tolerated with up to 44 months follow-up in patients with TN and R/R CLL/SLL. Currently, 66% of patients continue on ibrutinib. Clin Cancer Res; 23(5); 1149-55. ©2017 AACR. |
| مصطلحات الفهرس: | Humans, Piperidines, Pyrazoles, Pyrimidines, Adenine, Protein Kinase Inhibitors, Disease-Free Survival, Remission Induction, Dose-Response Relationship, Drug, Aged, 80 and over, Female, Male, Leukemia, Lymphocytic, Chronic, B-Cell, Drug-Related Side Effects and Adverse Reactions, Rare Diseases, Orphan Drug, Lymphoma, Hematology, Clinical Trials and Supportive Activities, Cancer, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Oncology and Carcinogenesis, Oncology & Carcinogenesis, article |
| URL: | |
| الإتاحة: | Open access content. Open access content CC-BY |
| ملاحظة: | application/pdf Clinical cancer research : an official journal of the American Association for Cancer Research vol 23, iss 5, 1149-1155 1078-0432 |
| أرقام أخرى: | CDLER oai:escholarship.org:ark:/13030/qt9kj7h1hd qt9kj7h1hd https://escholarship.org/uc/item/9kj7h1hdTest https://escholarship.orgTest/ 1377981702 |
| المصدر المساهم: | UC MASS DIGITIZATION From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1377981702 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |